With one of the most respected company names in the world and almost three-quarters of Wall Street analysts rating the company a ��uy,��Google (NASDAQ:GOOG) is hardly a diamond in the rough. Shares have climbed 51 percent in the past year; however, do Google�� earnings and growth potential justify such a high price? Let�� use our CHEAT SHEET investing framework to decide whether Google is an OUTPERFORM, WAIT AND SEE, or STAY AWAY.
C = Catalysts for the Stock�� MovementDespite Google Glass, self-driving cars, and all of the other cutting-edge products in Google�� pipeline, its core business operation is still its search engine. Its cash cow is advertising revenue from searches, which generates around 95 percent of its profits. Googles�� greatest growth prospect in the coming years is online mobile advertising. The company is strongly positioned to capitalize on two key trends in the coming years: the increased use of mobile internet search in emerging markets and innovations in advertising that will generate higher ��er click��margins. With an already-dominant market share, Google is right where it needs to be to take advantage of a growing user base and higher margins in mobile advertising. Should You Be Feeling Lucky About
Top 10 Blue Chip Stocks To Invest In Right Now: Westinghouse Air Brake Technologies Corp (WAB)
Westinghouse Air Brake Technologies Corporation (Wabtec), doing business as Wabtec Corporation, is a providers of value-added, technology-based equipment and services for the global rail industry. It provides its products and services through two business segments: the Freight Group and the Transit Group, both of which have different market characteristics and business drivers. Effective November 18, 2011, Wabtec acquired Fulmer Company, a manufacturer of motor components for rail, power generation and other industrial markets. Effective November 3, 2011, Wabtec acquired Bearward Engineering, a manufacturer of cooling systems and related equipment for power generation and other industrial markets. On June 29, 2011, the Company acquired an aftermarket transit parts business from GE Transportation, a parts supply business for propulsion and control systems for the passenger transit car aftermarket in North America. On February 25, 2011, the Company acquired Brush Traction Group, a provider of locomotive overhauls, services and aftermarket components. In July 2012, it acquired Tec Tran Corp. and its affiliates. In October 2012, it acquired LH Group. Effective July 30, 2013, Westinghouse Air Brake Technologies Corp acquired Turbonetics Inc, a manufacturer of turbochargers and components. Effective September 24, 2013, Westinghouse Air Brake Technologies Corp acquired Longwood Industries Inc.
The Freight Group manufactures and services components for freight cars and locomotives, builds new switcher locomotives, rebuilds freight locomotives, supplies railway electronics, positive train control equipment, signal design and engineering services, and provides related heat exchange and cooling systems. Its customers include railroads, leasing companies, manufacturers of original equipment, such as locomotives and freight cars, and utilities. During the year ended December 31, 2011, the Freight Group accounted for 61% of its total sales, with about 75% of its sales in North America and the remainder! to international customers.
The Transit Group manufactures and services components for new and existing passenger transit vehicles, which include subway cars and buses, builds new commuter locomotives and refurbishes subway cars. Customers include public transit authorities and municipalities, leasing companies, and manufacturers of subway cars and buses globally. During 2011, the Transit Group accounted for 39% of its total sales, with about half of its sales in North America and the remainder to international customers. During 2011, about 66% of the Transit Group�� sales are in the aftermarket and the remainder in the original equipment market.
The Company�� specialty products and electronics include positive train control equipment and electronically controlled pneumatic braking products; railway electronics, including event recorders, monitoring equipment and end of train devices; signal design and engineering services; freight car truck components; draft gears, couplers and slack adjusters; air compressors and dryers; heat exchangers and cooling products for locomotives and power generation equipment, and track and switch products. Its brake products include railway braking equipment and related components for freight and transit applications, and friction products, including brake shoes and pads. Its remanufacturing, overhaul and build products include new commuter and switcher locomotives, and transit car and locomotive overhaul and refurbishment. Its transit products include rail and bus door and window assemblies; accessibility lifts and ramps for buses and subway cars, and traction motors.
The Company competes with Knorr-Bremse AG, Electro-Motive Diesel, GE Transportation Systems and Faiveley Transport.
Advisors' Opinion:- [By Holly LaFon]
Another area that is intriguing to us is the North American energy sector which looks to have a number of interesting catalysts currently. While the energy sector is at present only a modest overweight in the portfolios, we have been encouraged by several trends taking place for a number of years. These positive developments are also having an impact that goes far beyond the energy sector itself. Many believe that the U.S. will become energy independent and possibly a net exporter of natural gas and oil (currently restricted by law) in the next decade. This opinion is based primarily on the development of new drilling techniques (i.e. horizontal drilling, and high pressure fracking) that have enabled companies to access oil and natural gas reserves in shale formations that were previously not economically viable. The ability to tap into this acreage is a game-changer in our view and is already having a tremendous impact on the economy. Employment rates in these mostly rural areas surrounding the shale basins are very high and companies thus find hiring extremely competitive. Strong labor markets tend to create strong local economies. Oil States International (OIS) has been able to capitalize on this trend by providing housing and other services to oil service workers that are in demand in the area. CST Brands (CST) operates gas stations in Texas, but it is increasingly looking to broaden its product offering beyond fuel. Rail companies like Union Pacific (UNP), Canadian Pacific (CP), Kansas City Southern (KSU) and Genesee and Wyoming (GWR) have also benefited substantially. Given that shale areas are rural and often lacking infrastructure, substantial investment must be made to support drilling and production activities. Without pipelines in place, railroads have been the primary takeaway mechanism for moving production to the various clusters of refining capacity around the United States. In order to serve this demand, massive investment in railcars has been nee
Best Stocks To Buy Right Now: MyEcheck Inc (MYEC)
MyECheck, Inc. (MyECheck), incorporated on May 18, 2005, is an electronic transaction data processor. The Company provides an alternative payment solution to paper checks, cards or ACH payments. MyECheck utilizes a method of clearing check data for payments. MyECheck offers implemented solutions that enable real-time payments by authorized electronic check. MyECheck�� electronic check service creates and clears checks using only customer account data without the hassle and delays of paper checks. MyECheck's system enables more payers - any authorized signor on any United States checking account, for any amount. MyECheck's transactions can even be payment guaranteed.
Electronic Check Service
Payer check data is collected by the Merchant either at customer registration, or on their Website, through a mobile device, or over the telephone, and is transmitted in real-time, or in batch to MyECheck for processing. MyECheck uses technology to generate electronic checks in accordance with the Federal Reserve Check 21 specification, and transmits the items to clear through the electronic check clearing system to the Merchant's account at one of its partner banks.
Check Authorization Service
MyECheck offers Check Authorization Service that enables merchants to verify consumer provided data, check the status of their customer�� bank account, provide evidence that the consumer has authorized the check and predict the likelihood of a check being returned unpaid. Transactions are immediately and automatically evaluated and approved or declined based upon the real time results of multiple fraud control tools. Businesses that accept MyECheck payments can use this service to provide an automated real time check authorization to mitigate returned items.
Check Guarantee Service
The check guarantee provider warranties all approved checks and reimburses the Payee (Merchant) for financial losses incurred as a result of returned checks. The C! heck Guarantee Provider buys the returned checks that have been warranted from merchants for the full face value of the returned checks. MyECheck merchants utilize Check Guarantee Service so that they can ship products or provide services immediately without having to wait to determine if the check will be returned unpaid. The Check Guarantee Service also eliminates the need for Merchants to collect on returned checks from their customers.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Rewards Nexus Inc (OTCMKTS: ERNI), MyEcheck Inc (OTCMKTS: MYEC) and ITonis Inc (OTCMKTS: ITNS) fell 29.6%, 18.92% and 9.09%, respectively, last Friday. Moreover, some of these small cap stocks are already making big moves again this morning - perhaps in part because they have all been the subject of recent paid promotions. So where are these small cap heading this week and for the long term? Here is a quick reality check:
Best Stocks To Buy Right Now: Swift Transportation Company(SWFT)
Swift Transportation Company, through its subsidiary, Swift Transportation Co., LLC, operates as a multi-faceted transportation services company and truckload carrier in North America. The company offers its truckload services through dry van, temperature-controlled, flatbed, and specialized trailers; and rail intermodal services. It also provides freight brokerage and logistics management services to other trucking companies, as well as leases tractors and offers repair services. As of December 31, 2011, the company operated a tractor fleet of approximately 15,900 units, including 11,900 tractors driven by company drivers and 4,000 owner-operator tractors; 50,600 trailers; and 6,200 intermodal containers in the United States and Mexico. It serves various industries, such as retail, discount retail, consumer products, food and beverage, manufacturing, and transportation and logistics industries. The company, formerly known Swift Holdings Corp., and was founded in 1966 and is headquartered in Phoenix, Arizona.
Advisors' Opinion:- [By Jake L'Ecuyer]
Swift Transportation (NYSE: SWFT) was also down, falling 6.83 percent to $21.95 after the company released some poor guidance after the close on Thursday.
Best Stocks To Buy Right Now: LinnCo LLC (LNCO)
Linn Co, LLC (Linn Co) sole purpose is to own LINN Energy, LLC (LINN) units. LINN is independent oil and natural gas company. LINN is focused on the development and acquisition of oil and natural gas properties, which include various producing basins within the United States. LINN�� properties are located in eight operating regions, which include Mid-Continent, which includes properties in Oklahoma, Louisiana and the eastern portion of the Texas Panhandle; Hugoton Basin, which includes properties located primarily in Kansas and the Shallow Texas Panhandle; Green River Basin, which includes properties located in southwest Wyoming; Permian Basin, which includes areas in west Texas and southeast New Mexico; Michigan/Illinois, which includes the Antrim Shale formation in the northern part of Michigan and oil properties in southern Illinois; California, which includes the Brea Olinda Field of the Los Angeles Basin; Williston/Powder River Basin, which includes the Bakken formation in North Dakota and the Powder River Basin in Wyoming, and East Texas, which includes properties located in east Texas. On March 30, 2012, the Company acquired certain oil and natural gas properties (Properties) located primarily in the Hugoton Basin of Southwestern Kansas from BP America Production Company (BP). On May 1, 2012, LINN completed the acquisition of certain oil and natural gas properties located in east Texas. In December 2013, Linn Energy LLC and Linn Co, LLC (Linn Co) announced the completion of the merger between LinnCo and Berry Petroleum Company (Berry), where LinnCo had acquired all of Berry's interest.
During the year ended December 31, 2011, LINN drilled a total of 294 gross wells. As of June 1, 2012, LINN had interests in approximately 15,000 gross productive wells (approximately 71% operated) and approximately 1.8 million net acres across seven regions in the United States.
Advisors' Opinion:- [By Ben Levisohn]
Shares of Linn Energy have gained 0.6% to $28.45 at 3:12 p.m. today, while LinnCo (LNCO) has risen 0.4% to $27.59. ExxonMobil has fallen 0.5% to $101.52.
- [By Matt DiLallo]
It's time alone at the top didn't last long; its industry peer LINN Energy (NASDAQ: LINE ) recently announced that it too was moving to monthly payouts. LINN Energy basically created the oil and gas MLP space when it went public and it has been delivering both income and returns to investors ever since. Last fall while Vanguard was implementing its monthly distribution policy, LINN was busy creating LinnCo (NASDAQ: LNCO ) which has really become a game changer for its business model.
Best Stocks To Buy Right Now: Guggenheim CurrencyShares Australian Dollar Trust (FXA)
Guggenheim CurrencyShares Australian Dollar Trust, formerly The CurrencyShares Australian Dollar Trust, is a grantor trust. The Trust issues shares (the Shares) in blocks of 50,000 (a Basket) in exchange for deposits of Australian Dollars and distributes Australian Dollars in connection with the redemption of Baskets. The investment objective of the Trust is for the Shares to reflect the price of Australian Dollars plus accrued interest, if any, less the expenses of the Trust�� operations. The Shares are intended to offer investors an opportunity to participate in the market for the Australian Dollar through an investment in securities. The Shares are bought and sold on New York Stock Exchange (NYSE) Arca like any other exchange-listed security.
The Trust holds Australian Dollars and, from time to time, issues Baskets in exchange for deposits of Australian Dollars and distributes Australian Dollars in connection with redemptions of Baskets. The Sponsor of the Trust oversees the performance of the Trustee and the Trust�� principal service providers. The Sponsor is Rydex Specialized Products LLC. The Sponsor is responsible for payment of administrative and marketing expenses. The Bank of New York Mellon serves as the Trustee. The Trustee is responsible for the day-to-day administration of the Trust, including keeping the Trust�� operational records. JPMorgan Chase Bank, N.A., London Branch is the Depository.
Advisors' Opinion:- [By Richard Cox]
Finally, the Australian Dollar has moved to new lows for the year, and prices in the AUD/USD will be forced to contend with another 61.8% Fib retracement (of the move from 0.8060 seen in 2010). This suggests the declines are in need of a corrective bound and equates to a bearish bias in the CurrencyShares Australian Dollar Trust (FXA).
- [By Dr. Duru]
The closest real justification for the rate cut comes via the stubbornly high exchange rate of the Australian dollar (FXA) and low credit demand:
The exchange rate, on the other hand, has been little changed at a historically high level over the past 18 months, which is unusual given the decline in export prices and interest rates during that time. Moreover, the demand for credit remains, at this point, relatively subdued.
- [By Dr. Duru]
So, the slight change of wording in the first sentence of the statement is important in that it could be a precursor to other upside adjustments in the RBA's language. If this happens, the Australian dollar (FXA) could take off…exactly what the RBA does not want. In fact, its desire to contain the currency must underlie the strained attempts to contain enthusiasm over the economy.
Best Stocks To Buy Right Now: BioTime Inc (BTX)
BioTime, Inc., incorporated on November 30, 1990, is a biotechnology company focused on the emerging field of regenerative medicine. Its commercial strategy is focused on its line of research products, such as ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, human embryonic stem (hES) cell lines, and royalties from Hextend. Its focus is to provide regenerative therapies for age-related degenerative diseases. In January 2011, the Company acquired the assets of Cell Targeting, Inc. (CTI), a biotechnology company focused on methods of painting molecules on the surface of cells, which in turn causes the cells to adhere to particular tissues, such as those afflicted with disease. On March 21, 2011, the Company acquired Glycosan BioSystems, Inc. (Glycosan) through a merger of Glycosan with OrthoCyte Corporation (OrthoCyte). Through the merger, OrthoCyte acquired all of Glycosan�� assets, including Glycosan�� Hystem hydrogel product line. In March 2011, the Company entered into an agreement with XenneX, Inc., pursuant to which it organized LifeMap Sciences, Inc. (LifeMap), a subsidiary formed to advance the development and commercialization of its human embryonic stem (hES) cell data base. In August 2011, four hES cell lines (ESI-035, ESI-049, ESI-051 and ESI-053) developed by its subsidiary ES Cell International (ESI) were approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. In May 2012, the Company acquired XenneX, Inc., through a merger of XenneX into LifeMap Sciences. In September 2012, the Company formed a wholly owned subsidiary, BioTime Acquisition Corporation. In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets to Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc.
HyStem is a biomaterial, which mimics the human extracellular matrix, which is the network of molecules surrounding cells in organs and tissues which is essent! ial to cellular function. Its HyStem hydrogels may have other applications when combined with the diverse and scalable cell types its scientists have isolated from hES cells. HyStem-Rx is a clinical grade formulation of HyStem-C, a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. Its subsidiary, OncoCyte Corporation, is developing PanC-Dx, a non-invasive blood-based cancer screening test designed to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check -ups. BioTime Asia, Limited (BioTime Asia) sells products for research use and may develop therapies to treat cancer and neurological and orthopedic diseases in Asia. OrthoCyte Corporation (OrthoCyte) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (ReCyte Therapeutics) is developing therapies for age-related cardiovascular and blood disorders. Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences), is a biotechnology company focused on developing stem cell-based therapies for retinal and other neurological disorders, including the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. LifeMap Sciences, Inc. (LifeMap) is advancing the development and commercialization of our embryonic stem cell database and plans to make the database available for the marketing of research products and for use by stem cell researchers at pharmaceutical and biotechnology companies and other institutions via paid subscriptions or on a fee per use basis.
The Company�� blood plasma expander product, Hextend, is a physiologically balanced intravenous solution used in the treatment of hypovolemia, a condition caused by low blood volume, often from blood loss during surgery or injury. Hextend maintains circulatory system fluid volume and blood pressure, and keeps vital organs perfused during surgery and t! rauma car! e. Hextend is manufactured and distributed in the United States by Hospira, Inc., and in South Korea by CJ CheilJedang (CJ), under license from it.
Human Embryonic Stem Cell Lines for Research Use
Combined with the Company�� ACTCellerate technology, it derives of a range of markets human embryonic progenitor cells (hEPCs). ESI�� six current good manufacturing practices (cGMP) hES cell lines have been approved by the NIH for inclusion in the Human Embryonic Stem Cell Registry, which renders those cell lines eligible for use in federally funded research. The ESI hES cell lines are available for purchase through www.biotimeinc.com. It also markets hEPCs developed using ACTCellerate technology. Its hEPCs are also available for sale through www.biotimeinc.com. It derived the complete genome sequence of five of the ESI hES cell lines to facilitate the development of products derived from these cell lines. It has made these GMP-grade cell lines, along with certain documentation and complete genomic deoxyribonucleic acid (DNA) sequence information, available for sale.
The Company offers human stem cell products and technology that can be used by researchers at universities and at companies in the bioscience and biopharmaceutical industries. It has developed research and clinical grade hES cell lines, which it markets for both basic research and therapeutic product development. It also markets human embryonic progenitor cell (hEPCs) developed using ACTCellerate technology. These hEPCs are purified lineages of cells, which are intermediate in the developmental process between embryonic stem cells and fully differentiated cells. The ACTCellerate cell lines are also available for purchase through http://www.biotimeinc.com.
Human Embryonic Progenitor Cells
Through the Company�� subsidiary ReCyte Therapeutics, it had a license from Advanced Cell Technology, Inc. (ACT) to use ACTCellerate technology, and the rights to market more than 200 human c! ell types! made using that process. ACTCellerate allows the rapid isolation of hEPCs, which are cells that are intermediate in the developmental process between embryonic stem cells and fully differentiated cells.
Through an agreement with ReCyte Therapeutics, Millipore Corporation became a global distributor of ACTCellerate hEPC lines. In addition to the products, which it is co-marketing with Millipore, it offers 92 other ACTCellerate hEPC lines for purchase at www.biotimeinc.com. Through its subsidiary LifeMap, it provides online biomedical database services to increase awareness of molecular markers and diverse cell types comprising its ACTCellerate hEPC lines. It also focuses to market additional cell types manufactured with its PureStem technology. PureStem cell lines are produced by the exogenous expression of specific transcription factors, which regulate the differentiation of cell types from hES or induced pluripotent stem (iPS) cells. BioTime Asia has an agreement with Shanghai Genext Medical Technology Co., Ltd. to sell ACTCellerate hEPC lines and related ESpan growth media to the medical and biological research communities in China, Taiwan, Hong Kong, and Macau on an exclusive basis. The marketing agreement includes provisions for an initial stocking inventory and annual milestones to maintain exclusivity. The Company�� California Institute of Regenerative Medicine (CIRM)-funded research addresses the need for industrial scale production of purified therapeutic cells.
hES Cells Carrying Genetic Diseases
The Company focuses to add to its product line muscle progenitor cells produced from five hES cell lines carrying genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker muscular dystrophy. It obtained the diseased hES cell lines from Reproductive Genetics Institute (RGI).
ESpan Cell Growth Media
The Company is marketing a range of! cell-gro! wth media products called ESpan. These growth media are optimized for the growth of hEPC types. Cells need to be propagated in liquid media, in both the laboratory setting, where basic research on stem cells is performed, and in the commercial sector. Its ESpan products are marketed through Millipore and Genext.
ESpy Cell Lines
The Company focuses for development of ESpy cell lines. The ability of the ESpy cells to emit light will allow researchers to track the location and distribution of the cells in both in vitro and in vivo studies.
HyStem Hydrogel for Research and HyStem-Rx for Cell Delivery Medical Devices
HyStem is a patented biomaterial that mimics the ECM, the network of molecules surrounding cells in organs and tissues that is essential to cellular function. Its HyStem technology forms the foundation for stem cell delivery products in both the adult and embryonic stem cell marketplace, including products manufactured using its ACTCellerate technology. As an injectable product, HyStem-Rx may address need in cosmetic and reconstructive surgeries and other procedures by transplanting adipose derived cells or other adult stem cells. The transfer of cells in HyStem-Rx localizes the transplanted cells at the intended site and by providing a three-dimensional scaffold upon which cells can rebuild normal tissue. HyStem-Rx may support other emerging cell and tissue transplant therapies, such as those derived from hES and iPS cells, in addition to its potential application in the treatment of a range of conditions such as osteoarthritis, brain tumors, stroke, bone fracture, and wounds.
Advisors' Opinion:- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company BioTime (NYSEMKT: BTX ) has received the dreaded one-star ranking.
- [By John Udovich]
Stem cell stocks have not exactly been the best performers lately in part because the controversy over their use has died down over the years while major breakthroughs have been few or far between, but the industry along with small cap stem cell stocks Pluristem Therapeutics Inc (NASDAQ: PSTI), BioTime, Inc (NYSEMKT: BTX) and BioRestorative Therapies (OTCBB: BRTX) are still quietly producing their share of news or minor breakthroughs worth taking note of. Just consider the following stem cell news or news from small cap players in the sector:
No comments:
Post a Comment